Comella Kristin, Bell Walter
US Stem Cell, Inc, Sunrise, FL, USA.
South African Stem Cell Institute, Parys, South Africa.
Int Med Case Rep J. 2017 Aug 16;10:295-299. doi: 10.2147/IMCRJ.S142514. eCollection 2017.
Stromal vascular fraction (SVF) is a mixture of cells which can be isolated from a mini-lipoaspirate of fat tissue. Platelet-rich plasma (PRP) is a mixture of growth factors and other nutrients which can be obtained from peripheral blood. Adipose-derived stem/stromal cells (ADSCs) can be isolated from fat tissue and expanded in culture. The SVF includes a variety of different cells such as ADSCs, pericytes, endothelial/progenitor cells, and a mix of different growth factors. The adipocytes (fat cells) can be removed via centrifugation. Here, we describe the rationale and, to our knowledge, the first clinical implementation of SVF and PRP followed by repeat dosing of culture-expanded ADSCs into a patient with severe xerostomia postirradiation.
Approximately 120 mLs of adipose tissue was removed via mini-lipoaspirate procedure under local anesthetic. The SVF was prepared from half of the fat and resuspended in PRP. The mixture was delivered via ultrasound directly into the submandibular and parotid glands on both the right and left sides. The remaining 60 mLs of fat was processed to culture-expand ADSCs. The patient received seven follow-up injections of the ADSCs plus PRP at 5, 8, 16, 18, 23, 28, and 31 months postliposuction. The subject was monitored over a period of 31 months for safety (adverse events), glandular size via ultrasound and saliva production.
Throughout the 31-month monitoring period, no safety events such as infection or severe adverse events were reported. The patient demonstrated an increase in gland size as measured by ultrasound which corresponded to increased saliva production.
Overall, the patient reported improved quality of life and willingness to continue treatments. The strong safety profile and preliminary efficacy results warrant larger studies to determine if this is a feasible treatment plan for patients postradiation.
基质血管成分(SVF)是一种可从少量脂肪抽吸物中分离得到的细胞混合物。富血小板血浆(PRP)是一种可从外周血中获取的生长因子和其他营养物质的混合物。脂肪来源的干/基质细胞(ADSCs)可从脂肪组织中分离并在培养中扩增。SVF包括多种不同细胞,如ADSCs、周细胞、内皮/祖细胞以及多种不同生长因子的混合物。脂肪细胞(脂肪细胞)可通过离心去除。在此,我们描述了将SVF和PRP联合应用,并随后对培养扩增的ADSCs进行重复给药,用于一名放疗后严重口干患者的基本原理,据我们所知,这是首次临床应用。
在局部麻醉下,通过小型脂肪抽吸术去除约120毫升脂肪组织。从一半脂肪中制备SVF,并将其重悬于PRP中。将混合物通过超声直接注入左右两侧的颌下腺和腮腺。剩余60毫升脂肪用于培养扩增ADSCs。患者在抽脂后第5、8、16、18、23、28和31个月接受了七次ADSCs加PRP的后续注射。对该受试者进行了31个月的监测,观察安全性(不良事件)、通过超声测量的腺体大小以及唾液分泌情况。
在整个31个月的监测期内,未报告感染或严重不良事件等安全事件。通过超声测量,患者的腺体大小增加,这与唾液分泌增加相对应。
总体而言,患者报告生活质量有所改善,并愿意继续接受治疗。强大的安全性和初步疗效结果值得进行更大规模的研究,以确定这是否是放疗后患者可行的治疗方案。